euro adhoc: Marseille-Kliniken AG / quarterly or semiannual financial statement / - Turnover increases in 1st half of 2007/2008 fiscal year to EUR 112.1 m - Group result climbs to EUR 12.1 m - Equity ratio climbs to 33.8 % (E)

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

08.02.2008

Ad hoc release According to § 15 WpHG

Berlin, 8th February 2008. During the first half of the 2007/2008 fiscal year,
Marseille-Kliniken AG (Prime Standard, ISIN DE 0007783003, MKA) further enhanced
its turnover figures, reporting growth of EUR 4,2 m to EUR 112.1 m (previous
year´s figure: EUR 107.9 m). The group annual result by minority interests
improved from EUR 2.6 m during the previous year to EUR 12.1 m in the period
under review. This represents a result per share in the amount of EUR 1.00,
compared with EUR 0.22 the previous year. EBIT improved from EUR 8.2 m to EUR
12.5 m. EBITDAR increased from EUR 31.4 m to EUR 36.9 m. Shareholder equity as
per balance sheet rose to EUR 84.5 m, up from EUR 66.5 m in the previous
reporting period. This made it possible to increase the equity ratio once again,
to 33.8%. The last sale-and-leaseback transaction made it possible to reduce net
debt, from EUR 108.4 m in the same period last year to the current figure of EUR
66.4 m.

The capacity utilisation rate for the consolidated group rose from 89.7% to
92.5%.

Adjusted for start-up losses for the costs of care and the costs of
rehabilitation-facility downtime, the result according to DVFA/SG fell slightly,
down EUR 0.4 m from EUR 7.0 m to its current level of EUR 6.6 m. While the
rehabilitation area was able to improve its result by EUR 0.6 m for a balanced
result, the result in the care area was EUR 1.0 m lower. This was due to planned
expenditures in the quality management area, with the aim of further
improvements in bed occupancy, coupled with early servicing measures totalling
EUR 0.7 m. In addition to this, the increase in energy prices, EUR 0.5 m, was
for the most part of temporary effect as approx. 60% of the additional energy
costs were the consequence of lower average temperatures during the reporting
period and the resultant increase in energy consumption. According to DVFA/SG,
the result per share reached EUR 0.55, compared with EUR 0.63 during the
comparable period a year before. At the close of the reporting period, EBITDAR
was EUR 31.5 m, after EUR 33.1 m on the previous year. EBIT fell from EUR 12.3 m
to its current level, EUR 10.0 m.

The core segment of care is growing and was able to register growth of EUR 5.0 m
in turnover, for a total of EUR 86.8 m, compared with EUR 81.8 m on the previous
year. In terms of the result according to DVFA/SG, the care segment attained a
result of EUR 6.6 m (previous year: EUR 7.6 m). Capacity utilisation improved
over the previous year, to 93.6% (previous year´s figure: 92.6%).

In the rehabilitation area, the positive trend of the first quarter continued.
As a result of capacity reductions, turnover fell to EUR 25.3 m (previous year:
EUR 26.1 m). Capacity utilisation had a positive effect, with a market 11.7%
rise from 77.4% during the previous year to 89.9% for the period under review.
The result according to DVFA/SG is balanced, representing a EUR 0.6 m
improvement over the previous year (previous year´s figure: EUR -0.6 m). The
company continues to pursue the objective of finding a partner or buyer for its
rehabilitation area.

During the fiscal year in progress, three new facilities were opened with a
total of 310 beds (in Potsdam, Schömberg and Düsseldorf). Additional locations
are in the construction stage; bed capacity will also be added as the company
develops its assisted living offerings in the care segment. In the reporting
period under review, Marseille-Kliniken AG was able to expand its total number
of beds to 8,899 (+287), of which more than 85% are to be found in the care
area.

For the entire 2007/2008 fiscal year, the company remains committed to reaching
its forecast turnover figure of EUR 240 m, EBIT of EUR 24 m and pre-tax earnings
of EUR 18 m. The positive trend in occupancy of the company´s care facilities
will continue: the specialisation already successfully completed, together with
the company´s verifiable quality management, offers advantages over the
competition. Specifically, here speedier occupancy of existing expansion
facilities, compared with the both first half-year and the same period in the
previous year, will result in marked growth in turnover and falling start-up
losses. Rehabilitation has successfully weathered the turn of the tide and has
been trimmed to a sustainable core level in terms of capacities. Following the
first half-year, it can be anticipated that the results in the rehabilitation
area will no longer place the group under a strain during the fiscal year in
progress. Under its concept for Assisted Living, the company plans a distinct
expansion of capacities and the opening of additional facilities during the
current calendar year. In the area of in-patient care, three additional
facilities with a total of 430 beds are currently under construction.

Effective immediately, the complete Letter to Shareholders for the first half of
the 2007/2008 fiscal year can be found online, at www.marseille-kliniken.com.

End of the ad hoc release

Further inquiry note:
For further information, please contact:

Marseille-Kliniken AG Hillermann Consulting
Axel Hölzer Christian Hillermann
CEO Investor Relations for Marseille-Kliniken AG
Alte Jakobstraße 79/80 Poststraße 14/16
D-10709 Berlin, Germany D-20354 Hamburg, Germany
Tel.: +49 (0)30 / 246 32-400 Tel.: +49 (0)40 / 320 279 10
Fax: +49 (0)30 / 246 32-401 Fax: +49 (0)40 / 320 279 114
www.marseille-kliniken.com www.hillermann-consulting.de

end of announcement euro adhoc
--------------------------------------------------------------------------------

emitter: Marseille-Kliniken AG
Sportallee 1
D-22335 Hamburg
phone: +49(0) 40 51459 0
FAX: +49(0) 40 51459 701
mail: [email protected]
WWW: http://www.marseille-kliniken.de
sector: Pharmaceuticals
ISIN: DE0007783003
indexes: CDAX, Classic All Share, Prime All Share
stockmarkets: regulated dealing/prime standard: Börse Frankfurt, free trade:
Börse Berlin, Börse Stuttgart, Börse Düsseldorf, regulated
dealing: Börse Hamburg
language: English

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | OTB

print